Trimethylamine N-Oxide Aggravates Neuro-Inflammation via lncRNA Fendrr/miR-145-5p/PXN Axis in Vascular Dementia Rats
Yang Deng,Rui Duan,Ye Hong,Qiang Peng,Zhong-Yuan Li,Xiang-Liang Chen,Ying-Dong Zhang
DOI: https://doi.org/10.2147/jir.s479154
IF: 4.5
2024-10-22
Journal of Inflammation Research
Abstract:Yang Deng, 1, &ast Rui Duan, 2, &ast Ye Hong, 2, &ast Qiang Peng, 2 Zhong-Yuan Li, 2 Xiang-Liang Chen, 2 Ying-Dong Zhang 1 1 Department of Neurology, Nanjing First Hospital, China Pharmaceutical University, Nanjing, 210006, People's Republic of China; 2 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiang-Liang Chen, Department of Neurology, Nanjing First Hospital, Nanjing Medical University, No. 68, Changle Road, Nanjing, Jiangsu, 210006, People's Republic of China, Email Ying-Dong Zhang, Department of Neurology, Nanjing First Hospital, China Pharmaceutical University, No.68, Changle Road, Nanjing, Jiangsu, 210006, People's Republic of China, Email Purpose: Vascular dementia (VaD) is the second most common dementia in the world. An increasing number of studies have demonstrated the important role of long non-coding RNAs (lncRNAs) in VaD. Our previous investigation demonstrated that Trimethylamine-N-oxide (TMAO) exacerbates cognitive impairment and neuropathological alterations in VaD rats. Thus, we hypothesized that TMAO could play an injury role in VaD by regulating lncRNAs. Materials and Methods: The rats using the bilateral common carotid artery (2VO) model were administered TMAO (120 mg/kg) for 8 consecutive weeks, 4 weeks preoperatively and 4 weeks postoperatively. High-throughput sequencing was conducted to investigate the effects of TMAO treatment on lncRNA expression in rat hippocampus and bioinformatics analysis was performed to identify potential downstream targets. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the levels of lncRNA fetal-lethal noncoding developmental regulatory RNA (Fendrr), miR-145-5p, and paxillin (PXN). Learning and spatial memory capacities were measured, as well as inflammatory factors. Nissl staining was used to observe neuronal injury in the CA1 area of the hippocampus. Furthermore, we used the Fendrr loss-of-function assay, miR-145-5p gain-of-function assays and PXN loss-of-function assay to explore the mechanisms by which TMAO acts on VaD. Results: TMAO administration upregulated lncRNA Fendrr expression in the rat hippocampus, while the damaging effects of TMAO were counteracted after knockdown of Fendrr. Fendrr exhibits highly expressed in 2VO rats and sponged miR-145-5p, which targets PXN. Silencing of Fendrr or PXN, or promotion of miR-145-5p improved neurological function injury, reduced neuronal damage, as well as repressed inflammation response. Inhibition of miR-145-5p abrogated up Fendrr knockdown mediated influence on 2VO rats. Conclusion: The results of this study indicated that TMAO inhibits the miR-145-5p/PXN axis by increasing the Fendrr expression, thus exacerbating the development of VaD. Keywords: trimethylamine N-oxide, neuroinflammation, Fendrr, MiR-145-5p, PXN, vascular dementia Vascular dementia (VaD) is characterized by the loss of cognitive function caused by cerebrovascular and cardiovascular pathologic changes, mainly manifested as learning and memory dysfunction. 1 It has a poor prognosis, with a 5-year mortality rate of 61%, significantly higher than most dementia types. 2 The available therapeutic agents for VaD are cholinesterase inhibitors, but these drugs may cause a large range of adverse events, including headache, joint pain and gastrointestinal reactions, etc., 3 while whether they can improve the patients is uncertain. Meanwhile, previous studies have found that several regulatory mechanisms participate in the pathologic process of VaD, including inflammation, apoptosis, and oxidative stress. 4,5 Therefore, there is an urgent need to further explore the pathological changes of VaD and the need for possible therapeutic targets. Recently, several studies have suggested that gut microbiota may be one of the major risk factors for VaD susceptibility. 6,7 A study by Liu et al was the first to show that vascular dementia is mediated by gut microbiota and its metabolites. 8 Trimethylamine N-oxide (TMAO) is a specialized metabolite processed by the intestinal microbiota. The intestinal microbiota processed certain ingested substances such as L-carnitine into trimethylamine (TMA), which is followed by transformation to TMAO via hepatic flavin monooxygenase 3 (FMO3) within the intestines. 9 Importantly, studies have displayed that higher circulating TMAO is associated with cognitive decline and dementia. 10,11 For instance, plasma concentrations of TMAO w -Abstract Truncated-
immunology